Who
Richard C. Pfenniger Jr.
Director
Company insider
Files Form 4 as: Director, GeneDx Holdings; Director, Opko Health; Director, Fluent; Director, Cocrystal Pharma; Director, Asensus Surgical; Director, Gp Strategies; Director, BioCardia; Director, Wright Investors Service Holdings.
In numbers
- Trades disclosed
- 255
- Buys
- 11
- Sells
- 0
- Bought
- $471K
- Sold
- $0
- Companies
- 10
- Companies where not an officer
- 9
- First trade
- 2 Feb 2005
- Last trade
- 18 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 23 Jun 2026 | WGS GeneDx HoldingsProviders & Facilities | SEC FORM 4 Code M | —3,576 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | WGS GeneDx Holdingsoption or derivative · Providers & Facilities | SEC FORM 4 Code A | —4,248 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | WGS GeneDx Holdingsoption or derivative · Providers & Facilities | SEC FORM 4 Code M | —3,576 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | WGS GeneDx Holdingsoption or derivative · Providers & Facilities | SEC FORM 4 Code A | —4,248 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | WGS GeneDx Holdingsoption or derivative · Providers & Facilities | SEC FORM 4 Code M | —3,576 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | WGS GeneDx HoldingsProviders & Facilities | SEC FORM 4 Code M | —3,576 at $0.00 | filing |
| 18 Jun 2026filed 22 Jun 2026 | OPK Opko Healthoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 18 Jun 2026filed 22 Jun 2026 | OPK Opko Healthoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | FLNT FluentAdvertising & Marketing | SEC FORM 4 Code A | —30,096 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | FLNT FluentAdvertising & Marketing | SEC FORM 4 Code A | —30,096 at $0.00 | filing |
| 9 Jan 2026filed 13 Jan 2026 | COCP Cocrystal Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,410 at $0.00 | filing |
| 9 Jan 2026filed 13 Jan 2026 | COCP Cocrystal Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,410 at $0.00 | filing |
| 28 Oct 2025filed 30 Oct 2025 | COCP Cocrystal Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | $56K40,000 at $1.39 | filing |
| 28 Oct 2025filed 30 Oct 2025 | COCP Cocrystal PharmaBiotechnology | SEC FORM 4 Code A | —20,000 | filing |
| 18 Jun 2025filed 23 Jun 2025 | WGS GeneDx Holdingsoption or derivative · Providers & Facilities | SEC FORM 4 Code A | —3,576 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | WGS GeneDx Holdingsoption or derivative · Providers & Facilities | SEC FORM 4 Code M | —12,924 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | WGS GeneDx HoldingsProviders & Facilities | SEC FORM 4 Code M | —12,924 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | FLNT FluentAdvertising & Marketing | SEC FORM 4 Code A | —39,682 at $0.00 | filing |
| 2 May 2025filed 5 May 2025 | WGS GeneDx Holdingsoption or derivative · Providers & Facilities | SEC FORM 4 Code M | —918 at $0.00 | filing |
| 2 May 2025filed 5 May 2025 | WGS GeneDx HoldingsProviders & Facilities | SEC FORM 4 Code M | —918 at $0.00 | filing |
News
Greenberg Traurig Advises OPKO Health on $722M+ Agreement to Sell Select BioReference Health Assets to LabcorpOPK · prnewswire.com · 21 Oct 2026Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference HealthOPK · prnewswire.com · 15 Oct 2026
0 headlines in the last 90 days name Richard C. Pfenniger Jr.; 2 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.